Introduction: Metabolic syndrome (MS) is associated with increased cardiovascular risk. There are a lot of study that is releated with the correlation between metabolic syndrome and low grade inflammation. We have attempted to compare Framingham Risk ...
Introduction: Metabolic syndrome (MS) is associated with increased cardiovascular risk. There are a lot of study that is releated with the correlation between metabolic syndrome and low grade inflammation. We have attempted to compare Framingham Risk Score(FRS) that calculates cardiovascular risc rates and Matrix Metalloproteinase- 9 levels that is an aterosclerotic proinflammatory marker, on metabolic syndrome`s between other healties. Method: We included 86 patients that contains 51 MS and 35 healties to this study..In both groups, age, length, weight, BMI, waist circumference, familial hearth disease and HT on family was registered. Framingham risk score (FRS) was calculated. Insulin, glucose, HOMA-IR, total cholesterol, LDL, HDL, Triglyceride levels saved. Blood samples for MMP -9 levels were taken and stored at -80 ℃. MMP-9 levels measured by the way of solid phase platinium ELISA (BIOSOURCE). Results: This case contained 86 patients, 51 of them is MS (%59.3) and the others are called as control group (%40.7). Ages of patients are changed between 20-55 years and the mean age is 38.52±10.02. FRS of MS patients were calculated statistically high compaired to control group (p=0.017). MMP-9 levels of MS patients were calculated statistically high compaired to control group (p=0.001).In both goups, there is no statistically significant relationship between MMP-9 levels and FRS (p>0.05) Conclusion: MMP-9 changes between the groups of MS young aged of 20-55 and health group may show us early atherosclerosis. At the group of high MMP-9 levels, even age releated cardiovasculary hearth disease risks are lower, risk was statistically calculated high compared to the other healthy populations. This situation is important in order to control risk factors as MS at early ages.